Domestic and foreign price comparison of Adalimumab in 2025

As of2025, adalimumab (Adalimumab) has been included in Category B of the National Reimbursement List in China, and the original drug Humira and a number of domestic biosimilar drugs are on the market. After the medical insurance negotiation, the price of each original drug (40mg) is about 1290 yuan, while the domestic drug The prices of similar drugs such as Glori, An Jianning, and Su Lixin range from 1,150 yuan to 1,250 yuan. After being included in medical insurance, the actual out-of-pocket burden of patients is further reduced. In some areas, the reimbursement rate can reach 70%, with each out-of-pocket payment of approximately 300 to 400 yuan. For most families, the financial pressure is significantly reduced.

In overseas markets, especially the United States, the price of adalimumab remains high. The price of the original Humira each is around 4,000 US dollars, which is equivalent to about 28,000 yuan in RMB. However, as biosimilars have been launched in European and American countries, prices have begun to drop significantly. For example, similar drugs YUSIMRY in the U.S. market are priced at about USD 995 per pill, while some similar drugs in the European market are even as low as USD 700, forming a strong contrast with the original research.

In comparison, driven by medical insurance negotiations and domestic substitution, the burden on patients in China has been significantly lower than that in the European and American markets. Although the price of original drugs has been gradually reduced abroad, even the price of similar drugs in the United States is still several times higher than the price paid after medical insurance in China. For example, after being covered by medical insurance in the United States, patients still have to pay hundreds of dollars per dose, while domestic out-of-pocket payments are about 300 to 500 yuan. This allows Chinese patients to enjoy higher accessibility and cost-effectiveness.

As more domestically produced similar drugs to adalimumab are launched, competition in the domestic market will further intensify and prices may continue to drop. Globally, with the expiration of Humira's patent period, the widespread launch of similar drugs will also drive international market prices back to rationality. For Chinese patients, this trend means more products to choose from and a lighter financial burden in the future, which will help the continuity and compliance of long-term treatment.

Reference materials:https://www.drugs.com/donanemab.html